Switch theme
Sign up to access all valuation multiples
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
2014
n/a
LTM Revenue $10.8M
LTM EBITDA -$2.2M
$223M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nextbiomedical has a last 12-month revenue (LTM) of $10.8M and a last 12-month EBITDA of -$2.2M.
In the most recent fiscal year, Nextbiomedical achieved revenue of $6.9M and an EBITDA of $2.8M.
Nextbiomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nextbiomedical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $10.8M | XXX | $6.9M | XXX | XXX | XXX |
| Gross Profit | $6.7M | XXX | $4.2M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | -$2.2M | XXX | $2.8M | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | 41% | XXX | XXX | XXX |
| EBIT | -$2.5M | XXX | -$2.6M | XXX | XXX | XXX |
| EBIT Margin | -23% | XXX | -37% | XXX | XXX | XXX |
| Net Profit | $0.3M | XXX | $2.1M | XXX | XXX | XXX |
| Net Margin | 3% | XXX | 30% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $4.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nextbiomedical's stock price is KRW 41750 (or $30).
Nextbiomedical has current market cap of KRW 338B (or $245M), and EV of KRW 307B (or $223M).
See Nextbiomedical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $223M | $245M | XXX | XXX | XXX | XXX | $0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nextbiomedical has market cap of $245M and EV of $223M.
Nextbiomedical's trades at 32.2x EV/Revenue multiple, and 79.3x EV/EBITDA.
Equity research analysts estimate Nextbiomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nextbiomedical has a P/E ratio of 896.9x.
See valuation multiples for Nextbiomedical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $245M | XXX | $245M | XXX | XXX | XXX |
| EV (current) | $223M | XXX | $223M | XXX | XXX | XXX |
| EV/Revenue | 20.7x | XXX | 32.2x | XXX | XXX | XXX |
| EV/EBITDA | -103.2x | XXX | 79.3x | XXX | XXX | XXX |
| EV/EBIT | -88.3x | XXX | -85.9x | XXX | XXX | XXX |
| EV/Gross Profit | 33.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 896.9x | XXX | 118.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -187.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNextbiomedical's last 12 month revenue growth is 106%
Nextbiomedical's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Nextbiomedical's rule of 40 is -27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nextbiomedical's rule of X is 244% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nextbiomedical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 106% | XXX | 110% | XXX | XXX | XXX |
| EBITDA Margin | -20% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Growth | -139% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -27% | XXX | 146% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 244% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 98% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nextbiomedical acquired XXX companies to date.
Last acquisition by Nextbiomedical was XXXXXXXX, XXXXX XXXXX XXXXXX . Nextbiomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nextbiomedical founded? | Nextbiomedical was founded in 2014. |
| Where is Nextbiomedical headquartered? | Nextbiomedical is headquartered in South Korea. |
| Is Nextbiomedical publicy listed? | Yes, Nextbiomedical is a public company listed on KRX. |
| What is the stock symbol of Nextbiomedical? | Nextbiomedical trades under 389650 ticker. |
| When did Nextbiomedical go public? | Nextbiomedical went public in 2024. |
| Who are competitors of Nextbiomedical? | Similar companies to Nextbiomedical include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Nextbiomedical? | Nextbiomedical's current market cap is $245M |
| What is the current revenue of Nextbiomedical? | Nextbiomedical's last 12 months revenue is $10.8M. |
| What is the current revenue growth of Nextbiomedical? | Nextbiomedical revenue growth (NTM/LTM) is 106%. |
| What is the current EV/Revenue multiple of Nextbiomedical? | Current revenue multiple of Nextbiomedical is 20.7x. |
| Is Nextbiomedical profitable? | Yes, Nextbiomedical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nextbiomedical? | Nextbiomedical's last 12 months EBITDA is -$2.2M. |
| What is Nextbiomedical's EBITDA margin? | Nextbiomedical's last 12 months EBITDA margin is -20%. |
| What is the current EV/EBITDA multiple of Nextbiomedical? | Current EBITDA multiple of Nextbiomedical is -103.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
